The Centers for Medicare and Medicaid Services (CMS) released the 2025 Medicare Physician Fee Schedule (PFS) final rule and the 2025 Hospital Outpatient Prospective Payment System (OPPS) and ...
Welcome to the Cardiovascular (CV) Dyad Leadership Strategic Planning Series! In episode two of four, Dr. Tom Draper talks with Mr. Adam DeJong and Dr. Malissa Wood about efforts required in the ...
Wolfe NK, Schiff MD, Christopher AB, et al., on behalf of FORCE Investigators. The study made use of the FORCE (Fontan Outcomes Registry Using CMR Examinations) registry, which collects clinical and ...
Tetralogy of Fallot is the most common cyanotic congenital heart disease and requires surgical repair. Strategy and timing/type of intervention is variable and depends on clinical symptomatology and ...
Participation in ACC’s Reduce the Risk: PCI Bleed Campaign was associated with a significant reduction of bleeding events following PCI, according to a study published in Circulation: Cardiovascular ...
Benali K, Ninni S, Guenancia C, et al. After propensity score matching, patients who underwent catheter ablation (n = 288) and those treated with medical therapy alone (n = 288) did not present any ...
Herzig MS, Kennedy KF, Hawkins BM, Secemsky EA. The authors examined all patients undergoing peripheral vascular intervention for the indication of ALI in the National Cardiovascular Data Registry ...
A quantitative flow ratio (QFR)-guided strategy did not provide the same prognostic benefits as a fractional flow reserve (FFR)-guided strategy for patients with intermediate coronary stenosis, based ...
A biodegradable polymer sirolimus-eluting stent (BP-SES) was noninferior to currently-used second-generation drug-eluting stents (DES) in terms of target lesion failure (TLF) at one year in patients ...
Results from the FLASH trial demonstrate the noninferiority of artificial intelligence-based fully automated quantitative coronary angiography (AI-QCA)-assisted PCI compared with optical coherence ...
In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart ...
Two devices approved by the U.S. Food and Drug Administration (FDA) this year for tricuspid regurgitation (TR) are safe, effective and improve quality of life (QOL) at one year, according to studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback